Gourt > Health > Pharmacy > Drugs and Medications > E > Exenatide
Exenatide (also Exendin-4, marketed as Byetta) is the first of a new class of medications approved for the treatment of Type 2 diabetes. It is an incretin mimetic, which has glucoregulatory effects. It is to be used in conjunction with oral medications such as metformin and/or a sulfonylurea to improve glucose control. The medication is injected twice per day using a specially designed pen. The typical human response is both an improvement of the release of internal insulin by the pancreas and suppression of pancreas glucagon release, behaviors more typical of individuals without blood sugar control problems. In the presence of exenatide, these responses are greater when the blood sugar is elevated.
Development History
The known incretins, GLP-1 and GIP, normally produced by the small intestine are not suitable as a treatment because of their very short half-life. An incretin researcher, doing an online search for proteins of similar known amino acid structure noticed that exenatide, a protein in the saliva of the poisonous North American Gila monster reptile, had a similar structure. Further investigation revealed that injected exenatide triggered very similar responses to endogenous incretins yet had a relatively long physiologic response half-life. These observations lead to development of exenatide as a medical treatment.
More on [ Exenatide ]
Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study http://bit.ly/4D7KnM
Type2Friendly (Type2Friendly) Thu, 31 Dec 2009 12:41:43 -0000
Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study http://bit.ly/4D7KnM
Boston: Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA® in DURATION-5 Study http://bit.ly/6oLQyE
Boston_CP (Boston CP) Tue, 29 Dec 2009 15:03:01 -0000
Boston: Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA® in DURATION-5 Study http://bit.ly/6oLQyE
Byetta Pancreatitis Risk Needs Further Studies: FDA: Byetta (exenatide) is a type 2 diabetes drug that is used .. http://bit.ly/66aNbg
caliandrea (yolanda n powell) Mon, 28 Dec 2009 16:27:31 -0000
Byetta Pancreatitis Risk Needs Further Studies: FDA: Byetta (exenatide) is a type 2 diabetes drug that is used .. http://bit.ly/66aNbg
Byetta - Manufacturer's site describes this injectable agent used in treating type 2 diabetes.
Byetta (exenatide) - Listing for FDA approved drug therapies archives from CenterWatch.
Meta Description: [ Listing for Byetta (exenatide) in FDA Approved Drug Therapies Archives from CenterWatch Clinical Trials Listing Service ]
Exenatide (synthetic exendin-4) - Questions and answers about this injectable agent for the treatment of type 2 diabetes.
Exenatide Achieves Glycemic Control Equivalent to Glargine - Comparator study in which a noninsulin treatment has demonstrated similar blood glucose control to insulin for patients who are failing to achieve treatment targets on oral medications.
Exenatide Promotes Weight Loss in Overweight Diabetic Patients - Research article explains some additional benefits of the drug, Byetta, used to help treat type 2 patients.
MedlinePlus: Exenatide Injection - How this medication is used, precautions, side effects, storage, and what to do in case of an overdose.
Meta Description: [ Exenatide Injection ]
| Pancreatitis in Patients taking Byetta (Dec. 2007) | |
| Next Video | |
